Boston Scientific (NYSE:BSX) Sets New 1-Year Low – Here’s Why

Boston Scientific Corporation (NYSE:BSX)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $53.26 and last traded at $53.3350, with a volume of 643182 shares changing hands. The stock had previously closed at $53.93.

Wall Street Analyst Weigh In

BSX has been the topic of several analyst reports. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a report on Thursday, April 23rd. Mizuho lowered their price objective on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Weiss Ratings cut shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Citigroup lowered their price objective on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Finally, UBS Group lowered their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.91.

Boston Scientific Trading Down 0.9%

The company has a market cap of $79.46 billion, a price-to-earnings ratio of 22.35, a price-to-earnings-growth ratio of 0.99 and a beta of 0.62. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company’s 50-day moving average is $65.95 and its 200 day moving average is $83.68.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current year.

Hedge Funds Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the second quarter worth about $26,000. Main Street Financial Solutions LLC lifted its stake in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares in the last quarter. Ieq Capital LLC lifted its stake in shares of Boston Scientific by 97.0% in the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its stake in shares of Boston Scientific by 56.2% in the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after buying an additional 2,556 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.